Mediwhale

Mediwhale has developed and commercialized an AI-powered diagnostic platform that uses non-invasive retinal imaging to predict risks for cardiovascular disease, chronic kidney disease, several eye conditions (cataract/glaucoma/AMD/diabetic retinopathy), and biological age. Their lead product suite "Dr. Noon" has been validated with robust clinical evidence published in leading journals like The Lancet Digital Health and European Heart Journal Digital Health. The technology matches the accuracy of coronary artery calcium scoring by CT scan but without radiation or invasive procedures. It’s deployed across Korea (>60 hospitals) with reimbursement status secured there; regulatory approvals span Europe (CE mark), UK, Australia, Singapore, Indonesia, Thailand & Malaysia.